Zota Healthcare Share Price

Zota Health Care Limited is a diversified pharmaceutical company in India, primarily engaged in the development, manufacturing, marketing, and export of a comprehensive range of pharmaceutical products. The company supplies generics, over-the-counter (OTC) products, allopathic, ayurvedic, nutraceutical, wellness and health supplements, catering to domestic and international markets. Zota Health Care operates a state-of-the-art manufacturing facility in Surat’s Sachin SEZ and a rapidly expanding retail pharmacy chain under the Davaindia brand, making it a notable player in India’s healthcare landscape. The Zota Health Care share price on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Zota Health Care stock price often mirrors shifts in generic drug demand patterns, healthcare consumption trends, and investor views on the domestic pharma sector’s growth prospects. Factors such as the pace of retail pharmacy network expansion, competitive intensity from other pharma manufacturers, raw material price fluctuations (active pharmaceutical ingredients), and government policies on drug pricing and healthcare access influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Zota Health Care stock price movements.

Zota Health Care live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Zota Health Care live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Zota Health Care share price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Zota Health Care Limited Company Fundamentals

a. Company Background

Zota Health Care Limited was incorporated in 2000. The company’s registered office is located in Surat, Gujarat. The company was founded by Ketankumar Chandulal Zota in 1995 and was incorporated under the provisions of the Companies Act, 1956, having a permanent presence in India since the year 2000. Zota Health Care’s primary activity involves the development, manufacturing, marketing, and export of a wide range of pharmaceutical products. It initially focused on building a strong foothold in the generic pharma market before gradually expanding into ayurvedic, nutraceutical, OTC, and retail pharmacy segments. The company’s business vertices include Manufacturing, Trading, and Export of Pharmaceutical Products. Over the years, Zota Health Care has significantly expanded its product portfolio and retail footprint through its Davaindia pharmacy chain. It operates in a competitive environment, with pricing and distribution governed by market forces and regulatory frameworks. The company has consistently focused on enhancing its manufacturing capabilities to meet the growing demand for quality healthcare products in India and globally. Zota Health Care currently employs 519 people and is headquartered in Surat, India.

b. Product Lines

• Generic pharmaceutical formulations including tablets, capsules, liquids, dry syrups, injectables, soft gel capsules, and cardiac products

• Over-the-counter (OTC) products for self-medication and wellness applications

• Allopathic medicines for a variety of therapeutic categories

• Ayurvedic products for traditional and herbal healthcare applications

• Nutraceutical and health supplements for preventive healthcare and wellness

• Wellness products across multiple health categories

• Products manufactured at state-of-the-art WHO-GMP certified facility in Surat’s Sachin SEZ

• Total of 6 patent products and 10 more products applied for patent in India

• Over 4,000 therapeutic product categories across approximately 24 divisions

• Portfolio catering to a variety of ailments across generics, OTC, allopathic, ayurvedic, and nutraceutical categories

c. Company Revenue Model

• Primary revenue from the manufacturing, trading, and export of pharmaceutical products to domestic and international markets

• Volume-driven revenue based on quantity of pharmaceutical formulations supplied across generics, OTC, and specialty segments

• Pricing determined by raw material costs (active pharmaceutical ingredients), product complexity, and market demand

• Revenue from the Davaindia retail pharmacy chain operating through Company-Owned Company-Operated (COCO) and Franchise-Owned Franchise-Operated (FOFO) store models

• Revenue from both domestic Indian market serving healthcare needs across the country and international exports to more than 30 countries

• Expanding retail pharmacy network contributing to new customer acquisition and revenue streams through direct-to-consumer sales

• Focus on increasing value-added product share including patented products and specialty formulations to drive better margins

• Investment in new manufacturing technologies and product development to enhance production capacity

• Raw material price fluctuations and regulatory changes influencing revenue stability

• Government policies on drug pricing and healthcare access influencing revenue stability

d. Geographic Presence

• Headquartered in Surat, Gujarat with registered office at Zota House, 2/896 Hira Modi Street, Sagrampura, Surat

• Manufacturing facility located at Sachin Special Economic Zone (SEZ), Surat, Gujarat (Plot No. 169, near Sachin Railway Station), equipped with high-tech machinery and WHO-GMP certifications

• Strong domestic market presence across India serving healthcare needs through pharma manufacturing and the Davaindia retail pharmacy chain

• Davaindia retail network operating 2,331 stores as of December 31, 2025, with a blend of COCO and FOFO stores across the country

• Global export presence to more than 30 countries worldwide

• Focus on expanding into new geographical areas through retail pharmacy chain expansion, with plans to open 1,200-1,500 stores over the next two years

• Operations primarily concentrated in western India with manufacturing based in Gujarat and retail presence expanding across the nation

e. Key Milestones

• 1995: Company founded by Ketankumar Chandulal Zota

• 2000: Incorporated as Zota Health Care Limited on July 12, 2000

• 2020-21: Received renewal of License to Work a Factory for Surat plant

• 2025: Achieved total revenue of ₹292.98 crore in FY 2024-25, up 62% YoY, with EBITDA at ₹16.07 crore

• 2025: Davaindia retail network scaled to 1,582 outlets in FY25, up from 880 the previous year

• 2025: Successfully closed Qualified Institutional Placement (QIP) at ₹350 crore for expanding retail pharmacy chain Dawa India, with plans to open 1,200-1,500 stores over the next two years

• 2025: Expanded Davaindia network to 2,331 stores as of December 31, 2025, adding 276 new stores in Q3 FY26

• 2025: COCO segment opened 231 stores in Q3 FY26, taking total COCO stores managed by wholly owned subsidiary Davaindia Health Mart to 1,207

f. Industry Perspective

Zota Health Care Limited operates in the pharmaceutical and healthcare industry, which is part of India’s broader healthcare sector. Globally, the pharmaceutical market continues to expand with the Asia-Pacific region being the fastest-growing market. In India, the pharma sector is poised for substantial growth. According to Pharma Trac, the Indian pharmaceutical market closed 2025 at ₹2,40,672 crore with 8.1% value growth, driven by cardiac, anti-diabetic, neuro, and respiratory therapies. A similar 7.8-8.1% growth is projected for 2026, driven by price hikes, new launches, and the expanding anti-obesity segment. The Indian pharmaceutical market was valued at USD 66.66 billion in 2025 and is projected to reach USD 88.86 billion by 2030, growing at a CAGR of 5.92%. The Economic Survey 2025-26 has observed that the Indian pharmaceutical industry is shifting from a volume-driven approach to a value-driven approach, moving up the value chain with greater emphasis on complex generics, biosimilars, and innovation. India’s medical devices sector is rapidly becoming globally competitive, with exports to 187 countries in FY25. The Indian pharmaceutical industry is well-positioned to sustain 7-9% growth, driven by robust domestic demand, stable export performance, and a steady transition towards complex generics, biosimilars, and specialty products. Key challenges include raw material price volatility, intense competition from domestic and international players, regulatory price controls, and the need for continuous R&D investment.

Zota Health Care Limited Stock Market Presence: Listings & Index Representation

Zota Health Care is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol ZOTA and on the Bombay Stock Exchange (BSE) with the scrip code 542650. Its listing on both exchanges ensures that the Zota Health Care price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company forms part of several benchmark indices that represent broad market segments. Zota Health Care is included in BSE SmallCap and BSE AllCap indices. Being represented in indices enhances the visibility and liquidity of the Zota Health Care price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India’s pharmaceutical landscape. The inclusion of Zota Health Care in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the Zota Health Care price to corporate and industry developments. The company’s ISIN code is INE358R01011 and face value is ₹10 per share.

Zota Health Care Limited Stock Performance and Share Price History

The Zota Health Care price has exhibited significant volatility over the past decade, shaped by the company’s expansion from a pharma manufacturer into a vertically integrated player with a retail pharmacy chain and broader healthcare industry cycles. The Zota Health Care share price recorded a total return of approximately 48.24% over the last 1 year, significantly outperforming the broader market indices, reflecting strong growth momentum. The Zota Health Care share price delivered a 3-year total return of 67.94% and a 5-year total return that has been positive, demonstrating substantial long-term wealth creation. The Zota Health Care share price reached a 52-week high of ₹1,740.00 and a 52-week low of ₹752.00, indicating a wide trading range and substantial price fluctuations. The Zota Health Care share price recorded a remarkable rally in 2024, while the subsequent period has seen the Zota Health Care price moderate and correct from its peak levels. The Zota Health Care share price has shown a 1-week return of approximately 6.26%, a 1-month return of -5.57%, and a 3-month return of -24.33% as of April 2026, indicating mixed short-term momentum.

The Zota Health Care price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 62% year-on-year revenue growth in FY25 and announced the successful closure of a ₹350 crore QIP for retail expansion, the Zota Health Care price showed a positive reaction. The Zota Health Care price has shown a pattern of strong positive momentum in periods when the company’s Davaindia store expansion announcements exceeded expectations, while periods of earnings moderation or concerns over regulatory headwinds have contributed to consolidation in the Zota Health Care price. Corporate developments, including strategic announcements such as the expansion of the Davaindia network to 2,331 stores, the acquisition of patent products, and the company’s focus on value-added formulations, have also influenced short-term fluctuations in the Zota Health Care price. The Zota Health Care share price has shown a 1-year return of approximately 48.24% as of April 2026, reflecting strong growth over the last year. The Zota Health Care share price has shown a 10-year aggregate net profit that has been improving in recent years, reflecting the company’s turnaround and expansion. The Zota Health Care share price reached its 52-week high of ₹1,740.00 before declining to its 52-week low of ₹752.00, reflecting the volatility inherent in the pharma space. The Zota Health Care price has shown a year-to-date return that has been negative as of April 2026, indicating pressure in the current fiscal year. Comprehending these patterns in the Zota Health Care price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Zota Health Care stock price movements illustrate how industry fundamentals, raw material price cycles, and investor expectations converge in market pricing.

The Zota Health Care share price has shown distinct seasonal patterns over the past decade. The best performing year historically was 2024 with a positive return, while the worst year was 2025 with a decline. Historically, the stock has shown positive annual returns in 6 out of the last 10 years. In terms of annual performance, the Zota Health Care share price delivered a 1-year return of 48.24%, a 3-year return of 67.94%, and a 5-year return that has been positive. The Zota Health Care share price has demonstrated that the stock tends to perform better in periods of strong healthcare demand and supportive government policies on generic drugs, while underperforming during phases of regulatory uncertainty and intense competition. The Zota Health Care stock price has shown a 3-year total return of 67.94%, indicating substantial wealth creation over this period. The Zota Health Care stock price has shown a 5-year total return that has been positive, reflecting the company’s ability to deliver returns across market cycles. The Zota Health Care stock price continues to trade at a significant discount from its 52-week high of ₹1,740.00, standing at around ₹1,085-1,129 levels as of April 2026.

Zota Health Care Limited Investor Relevance and Role in Portfolio

Zota Health Care holds a significant position for portfolio investors who seek exposure to India’s pharmaceutical sector with a focus on vertical integration across manufacturing and retail. The company’s presence in high-growth areas such as generics, ayurvedic products, and retail pharmacy chains aligns it with investment strategies that value healthcare access, affordability, and the government’s focus on generic medicines under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP). The Zota Health Care share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor retail store expansion, product pipeline, and raw material costs when evaluating allocation decisions.

Institutional stakeholders play an increasingly significant role in Zota Health Care’s ownership profile. As of December 2025, Promoters hold 50.64% of the company. Mutual funds hold 0.42% of the company. Foreign Institutional Investors (FIIs) hold 8.09% of the company, while Domestic Institutional Investors (DIIs) hold 6.80% of the company. Institutional investors as a whole have significantly increased their stakes, with FIIs increasing by 4.6% points to 8.1% and DIIs increasing by 2.3% points to 7.2% at the end of the December 2025 quarter. Retail and other shareholders hold approximately 34.06% of the company. Key institutional holders include foreign and domestic institutional investors who have doubled their stakes in this expanding pharma company. These investors represent a blend of domestic and international perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks.

Based on data, Zota Health Care exhibits varying levels of beta and volatility across different measurement periods. Based on data, the long-term beta (5-year monthly) stands at approximately 0.23 according to Yahoo Finance, indicating that the stock is generally less volatile than the broader market over an extended period. Based on data, the daily-one month beta shows moderate correlation, while the daily-three month beta indicates moderate sensitivity. Based on data, the weekly-one year beta is 1.07 according to TradingView, showing higher-than-market sensitivity in short-term trading. Based on data, the weekly-two year beta shows low correlation, and the 2 week-two year range beta is also low. Based on data, the monthly-two year beta continues to show moderate correlation. Supporting statistics include mean values across different periods and standard deviations indicating moderate variability. The average weekly movement stands at 7.4%, which is higher than the pharmaceuticals industry average of 5.9% and the market average of 6.4%, reflecting above-average volatility. Overall, the Zota Health Care stock price demonstrates a moderate-to-high volatility profile with beta values suggesting the stock tends to move with varying sensitivity to broader market direction over different time frames.

The Zota Health Care share price has shown periods of heightened responsiveness to sector-specific news and quarterly earnings releases. The Zota Health Care stock price’s beta reflects that the company’s established manufacturing capabilities and expanding retail network may provide some stability, though the pharmaceutical sector remains sensitive to raw material price fluctuations and regulatory changes.

Zota Health Care Limited Sectoral Relevance and Peer Positioning

The sector relevance of Zota Health Care is anchored in its role within the broader Indian pharmaceutical and healthcare industry, where it competes with other pharma manufacturers and retail pharmacy chains. As part of this industry, the company’s strategic positioning connects generics, OTC products, ayurvedic medicines, and nutraceuticals to patients and consumers across India and globally. Competitors in the pharmaceutical segment include companies such as Sun Pharmaceutical Industries Limited, Divi’s Laboratories Limited, Cipla Limited, Torrent Pharmaceuticals Limited, Dr. Reddy’s Laboratories Limited, Zydus Lifesciences Limited, Mankind Pharma Limited, and Aurobindo Pharma Limited. In the retail pharmacy space, competitors include Apollo Pharmacy and other organized pharmacy chains. Firms with parallels in either product range or distribution scale are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Zota Health Care P/E ratio have shown variations over different periods. The current P/E ratio is negative at approximately -70.41 (TTM) due to the company reporting losses in recent quarters, while the industry P/E stands at approximately 31.71. The mean historical P/E Ratio over the last five years has fluctuated, with the stock’s P/E ratio having changed with respect to the historical average. Periods when investors perceived improvements in profitability or earnings sustainability have corresponded with expansion in valuation multiples, whereas phases of moderation in earnings momentum or industry cyclicality have seen valuation contraction. The Zota Health Care P/E ratio reached 84.06 in recent periods according to some sources.

Similarly, Zota Health Care EPS has shown variation according to how operational performance aligns with industry demand cycles and cost structures. Structural gains from capacity expansion and retail network growth supported directional improvement in earnings per share during favourable conditions, while cyclical headwinds from raw material price volatility and competitive pressures have moderated EPS momentum. Zota Health Care earnings have shown a trajectory that responded to both volume growth and margin pressures over the analysed period. The diluted EPS has shown improvement, with net profit increasing to ₹8.62 crore in FY 2025 from ₹3.38 crore in FY 2024, a growth of 154.95%. However, the company has reported negative profit margins of -15.37% on a TTM basis, reflecting ongoing profitability challenges.

Zota Health Care market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and evolving pharmaceutical market. Over years, the Zota Health Care market cap has followed a pattern of significant growth. The market cap increased from approximately ₹4,046.79 crore as of April 2026. This growth mirrors the trend in the Zota Health Care share price and the broader performance of the pharmaceutical sector relative to broader market indices.

Zota Health Care earnings over the past several years have been characterised by a period of strong revenue growth with improving but still modest profitability. Total revenue increased from ₹168.64 crore in FY 2024 to ₹261.90 crore in FY 2025, representing a growth of 55.30% year-on-year. For the trailing twelve months (TTM) as of April 2026, revenue stood at ₹292.98 crore with net profit of ₹8.62 crore. The company’s consolidated revenue from operations recorded an impressive growth of 62% Year on Year, reaching ₹29,298 lakhs in FY 2025, up from ₹18,048 lakhs in FY 2024. EBITDA stood at ₹1,607 lakhs as compared to ₹828 lakhs during the preceding financial year. For the third quarter ended December 31, 2025, revenue stood at ₹14,466.8 million (approx ₹144.67 crore), up from ₹726.3 million in the previous year. The company’s gross profit increased from ₹8,379 lakhs in FY 2024 to ₹15,567 lakhs in FY 2025, an increase of 86%.

Zota Health Care EPS has shown variation over the past decade. The diluted EPS stood at ₹8.62 in FY 2025, up from ₹3.38 in FY 2024, representing a growth of 154.95%. The EPS growth rate has shown significant variation, with the company delivering positive profit growth in recent years. According to quarterly data, EPS was ₹4.04 for the June 2025 quarter (272.73% growth), ₹2.56 for the September 2025 quarter, and ₹4.04 for the December 2025 quarter.

The Zota Health Care P/E ratio has shown fluctuations over the available period. At the end of recent fiscal years, the P/E ratio has remained negative due to negative earnings on a TTM basis, with current levels at approximately -70.41x across different sources, while the industry P/E stands at approximately 31.71x. The mean historical P/E ratio over the last five years has been positive in some years and negative in others. The current negative P/E ratio compared to the historical average reflects that investor expectations are adjusting to near-term earnings headwinds. The Zota Health Care share price has been influenced by these valuation metrics. The Zota Health Care stock price continues to be evaluated in the context of its earnings potential and market position.

Summary

Zota Health Care Limited is a diversified pharmaceutical and retail healthcare company listed on both the NSE and BSE, where the Zota Health Care share price reflects pharma demand cycles, retail expansion, and product innovation within the healthcare sector. Its representation on stock exchanges supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader pharmaceutical industry themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s healthcare market.